ClinicalTrials.gg
Not yet recruitingNCT07854509Updated Oct 2, 2026

A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure

A Phase 2 interventional study of SKB264+SKB118 in Non-Squamous Non-Small Cell Lung Cancer, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 2, Interventional, and Treatment

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 26 under way, 9 of them phase 3. sacituzumab tirumotecan · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
14th of 26
110 · median 115
Started
2026
with 8 others
Phase 2
15 of 26
13 open now
Primary completion
2027-12
later than 14 of 25 live
Registered
26th of 26
by date
Lead sponsor
7 of 26
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Among the 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung, this one is the 14th largest by planned enrollment, is one of 9 that started in 2026, is one of 15 in phase 2, reaches primary completion later than 14 of the 25 other live ones, and was the 26th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About sacituzumab tirumotecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is an open-label, multicenter, Phase II clinical study to evaluate the safety, tolerability, and efficacy of SKB264 in combination with SKB118 in participants with locally advanced or metastatic non-squamous NSCLC harboring EGFR-sensitizing mutations who have failed EGFR-TKI therapy. The study includes a dose escalation phase and an expansion phase.

03

Conditions studied

  • Non-Squamous Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed locally advanced (Stage IIIB/IIIC) or (Stage IV) non-squamous NSCLC that is not suitable for radical surgery and/or radical radiotherapy (regardless of whether concurrent chemotherapy has been received).
  2. Confirmed EGFR-sensitizing mutations.
  3. Participants must have failed prior EGFR-TKI therapy for locally advanced or metastatic disease.
  4. Participants must be confirmed during the screening period to be able to provide a tumor tissue sample. If this cannot be met, acceptability should be discussed with the medical monitor.
  5. At least one as assessed by the investigator according to v1.1.
  6. performance status of 0 or 1.
  7. ≥ 12 weeks.
  8. Adequate bone marrow, liver, kidney, and coagulation function.
  9. Male and female participants must agree to use highly effective measures during the specified period of the study.

Exclusion criteria

Exclusion Criteria:

  1. or cytologically confirmed small cell lung cancer, neuroendocrine carcinoma, or sarcomatoid carcinoma components, or with a squamous component of more than 10%.
  2. Presence of known driver gene alterations with approved targeted therapies.
  3. Participants with known to meninges, brainstem metastases, spinal cord metastases and/or compression, active or untreated .
  4. Participants with other malignant tumors within 3 years prior to the first dose.
  5. Presence of uncontrolled, or symptomatic, or recurrent pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  6. History of (non-infectious) interstitial lung disease (ILD) or non-infectious pneumonia requiring therapy, current ILD or non-infectious pneumonia.
  7. Presence of other moderate to severe lung disorders that may interfere with the detection or management of drug-related pulmonary toxicity and severely affect respiratory function.
  8. Risk of developing esophago-tracheal fistula or esophago-pleural fistula, or tumor invasion or compression of surrounding vital organs and major blood vessels.
  9. History of hemorrhagic diathesis or coagulopathy and/or bleeding symptoms or risks.
  10. Previous or concurrent gastrointestinal diseases, surgery, and wound healing complications.
  11. Unresolved toxicity from prior anti-tumor therapy, defined as toxicity not recovered to Grade 0 or 1 of v6.0, or to the level specified in the inclusion/exclusion criteria, with the exception of alopecia.
  12. Serious infection within 4 weeks before the first dose, active infection requiring systemic anti-infective therapy within 2 weeks before the first dose.
  13. Presence of active or or co-infection with HBV and HCV.
  14. Positive (HIV) test or known history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.
  15. Known active tuberculosis.
  16. Known history of allogeneic organ transplant or hematopoietic stem cell transplant.
  17. With Grade ≥ 2 peripheral neuropathy.
  18. Active disease requiring systemic treatment within the past two years.
  19. Participants who have received any of the following systemic anti-tumor therapies (including in the or neoadjuvant setting):

    1. Prior treatment with , immune checkpoint agonists, or any therapy targeting the immune mechanism of the tumor, such as immune cell therapy.
    2. Prior treatment with PD-(L)1/VEGF bispecific antibodies or therapies targeting VEGF/VEGFR with monoclonal antibodies or small molecules.
    3. Therapy targeting TROP2.
    4. Any drug therapy targeting topoisomerase I, including antibody-drug conjugate (ADC) therapy.
  20. Pregnant or lactating women.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    SKB264 in combination with SKB118

    SKB264 (4 mg/kg or other dose levels) combined with SKB118 (10 mg/kg, 20 mg/kg, or other dose levels).

    Drug: SKB264+SKB118

Interventions

06

What researchers measure

Primary outcomes

  1. The safety of SKB264 in combination with SKB118 in participants with non-squamous non-small cell lung cancer (NSCLC)

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (per Common Terminology Criteria for Adverse Events \[CTCAE\] v6.0)

    Time frame: From enrollment to the end of treatment at 24 months

  2. ORR(objective response rate)

    ORR as assessed by the investigator based on RECIST v1.1

    Time frame: From enrollment to the end of treatment at 24 months

Secondary outcomes

  1. DCR(Disease control rate )

    as assessed by the investigator based on RECIST v1.1

    Time frame: From enrollment to the end of treatment at 24 months

  2. DOR(duration of response )

    as assessed by the investigator based on RECIST v1.1

    Time frame: From enrollment to the end of treatment at 24 months

  3. PFS(progression-free survival)

    as assessed by the investigator based on RECIST v1.1

    Time frame: From enrollment to the end of treatment at 24 months

  4. OS (overall survival)

    Time frame: From enrollment to the end of treatment at 24 months

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 14 months is below that.

Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartEst.
Oct 15, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2029
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07854509
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Oct 2, 2026

Study contacts

Xiaoping Jin, PhD
Contact
jinxp@kelun.com
028-67255495

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sacituzumab tirumotecan · Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001

Start the discussion